Adragos and Towa to Produce 1.5 Billion Tablets a Year
CDMO Adragos Pharma Kawagoe and Towa Pharmaceutical have agreed to a manufacturing partnership that will nearly triple solid-dosage capacity, shoring up Japan's fragile generics supply chain.
Adragos Pharma Kawagoe has signed a basic agreement with Towa Pharmaceutical to establish a strategic collaboration aimed at ensuring the stable supply of off-patent pharmaceuticals. Under the agreement, Adragos Pharma will promote contract manufacturing utilizing the Kawagoe plant and secure production capacity to supply up to 1.5 billion tablets per year for Towa Pharmaceutical on a planned basis.
As the importance of ensuring a stable supply of off-patent medicines continues to grow in Japan, Adragos Pharma believes that pharmaceutical contract manufacturers have an important role to play in supporting a more sustainable supply structure. Through this collaboration with Towa Pharmaceutical, the Company aims to contribute to the broader national effort to strengthen domestic manufacturing capacity, production resilience, and long-term supply stability.
Leveraging this partnership, Adragos Pharma will accelerate capital investment at the Kawagoe plant and expand annual solid-dosage capacity from the current 1.0 billion tablets to 2.5 billion tablets in stages. Of this total, capacity of approximately 1.5 billion tablets will be allocated to Towa Pharmaceutical. By sharing demand and supply forecasts, the two companies will work to ensure a stable supply of medicines.
Masanori Kurogome, Representative Director, Adragos Pharma Kawagoe, said: “Our collaboration with Towa Pharmaceutical represents an important partnership in supporting the stable supply of off-patent medicines. Through capital investment at our Kawagoe plant, we will further strengthen our production and quality assurance systems and, with quality as our highest priority, contribute to a more stable domestic supply of medicines. At the same time, this partnership will support the continued enhancement of our capabilities as a CDMO and our sustainable growth.”
Andreas Raabe, Founder and CEO, Adragos Pharma, added: “This agreement reflects the important role that specialized manufacturing partners can play in supporting the stable supply of medicines. By investing in our Kawagoe site and working closely with Towa Pharmaceutical, we aim to contribute to a stronger and more resilient supply framework for off-patent medicines in Japan.”
